A new study reveals a groundbreaking treatment for newly diagnosed multiple myeloma, achieving 100% response rates and minimal residual disease negativity.
Marc Raab, MD
Advertisement
Marc Raab, MD, is a professor of medicine and clinical director of the Heidelberg Myeloma Center Department of Medicine V, Heidelberg University Hospital.
Articles by Marc Raab, MD
Advertisement
Latest Updated Articles
Teclistamab Combos Are Encouraging in Frontline MyelomaPublished: October 13th 2025 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ESMO Trials Explore Treatment Sequencing in RCC
2
Uncovering Clinical Risk Factors for T-DXd Pneumonitis in Metastatic Breast Cancer
3
Glofitamab Plus Polatzumab Vedotin Demonstrates High Early Efficacy in LBCL
4
PHERFLOT Trial: Perioperative Promise in HER2+ Esophagogastric Adenocarcinoma
5
